Target Cd7 Car-T Cells
T-cell Acute Lymphoblastic Leukemia
920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaCell therapyEarly Phase 1Active
C
38/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 81/ 100
Competitive context
79 Active assets in the T-cell Acute Lymphoblastic Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
VINCRISTINE SULFATE Children's Oncology Group | Phase 3 | BB |
PEGASPARGASE Children's Oncology Group | Phase 3 | BB |
ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT) University of Washington | Phase 3 | BB |
MERCAPTOPURINE ANHYDROUS SWOG Cancer Research Network | Phase 3 | BB |
Daunorubicin SWOG Cancer Research Network | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Target Cd7 Car-T Cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →